Lyme vaccine

Issues and controversies

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The development of an effective vaccine for Lyme disease represents a major advance in the control of the most prevalent vector-borne disease in the United States. It has a definite place in the total approach to control of this disease. Its use should be restricted to individuals who are at moderate to high risk of exposure to infected vector ticks. Vaccinated individuals should not be complacent about other personal protection measures, because the vaccine is not uniformly effective and protective antibody levels decay rapidly. Booster doses will be necessary, but the intervals have not yet been determined. There is a theoretical concern about the possible induction of inflammatory arthritis through an autoimmune mechanism, but there is no evidence that this condition has clinical relevance. The impact of the current lawsuits on vaccine recommendations and use remains to be determined. Continued surveillance for rare long-term side effects should address the medical risk issue. Alternative primary vaccine administration schedules are currently under study, and could lead to regimens permitting achievement of protective immunity in 6 months or less. Vaccine is not approved for use in children under the age of 15 years.

Original languageEnglish (US)
Pages (from-to)171-187
Number of pages17
JournalInfectious Disease Clinics of North America
Volume15
Issue number1
DOIs
StatePublished - Jan 1 2001

Fingerprint

Vaccines
Lyme Disease Vaccines
Disease Vectors
Ticks
Arthritis
Immunity
Appointments and Schedules
Antibodies

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Lyme vaccine : Issues and controversies. / Rahn, Daniel Wallace.

In: Infectious Disease Clinics of North America, Vol. 15, No. 1, 01.01.2001, p. 171-187.

Research output: Contribution to journalArticle

@article{176ee5e000794622a447535d05628119,
title = "Lyme vaccine: Issues and controversies",
abstract = "The development of an effective vaccine for Lyme disease represents a major advance in the control of the most prevalent vector-borne disease in the United States. It has a definite place in the total approach to control of this disease. Its use should be restricted to individuals who are at moderate to high risk of exposure to infected vector ticks. Vaccinated individuals should not be complacent about other personal protection measures, because the vaccine is not uniformly effective and protective antibody levels decay rapidly. Booster doses will be necessary, but the intervals have not yet been determined. There is a theoretical concern about the possible induction of inflammatory arthritis through an autoimmune mechanism, but there is no evidence that this condition has clinical relevance. The impact of the current lawsuits on vaccine recommendations and use remains to be determined. Continued surveillance for rare long-term side effects should address the medical risk issue. Alternative primary vaccine administration schedules are currently under study, and could lead to regimens permitting achievement of protective immunity in 6 months or less. Vaccine is not approved for use in children under the age of 15 years.",
author = "Rahn, {Daniel Wallace}",
year = "2001",
month = "1",
day = "1",
doi = "10.1016/S0891-5520(05)70274-9",
language = "English (US)",
volume = "15",
pages = "171--187",
journal = "Infectious Disease Clinics of North America",
issn = "0891-5520",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Lyme vaccine

T2 - Issues and controversies

AU - Rahn, Daniel Wallace

PY - 2001/1/1

Y1 - 2001/1/1

N2 - The development of an effective vaccine for Lyme disease represents a major advance in the control of the most prevalent vector-borne disease in the United States. It has a definite place in the total approach to control of this disease. Its use should be restricted to individuals who are at moderate to high risk of exposure to infected vector ticks. Vaccinated individuals should not be complacent about other personal protection measures, because the vaccine is not uniformly effective and protective antibody levels decay rapidly. Booster doses will be necessary, but the intervals have not yet been determined. There is a theoretical concern about the possible induction of inflammatory arthritis through an autoimmune mechanism, but there is no evidence that this condition has clinical relevance. The impact of the current lawsuits on vaccine recommendations and use remains to be determined. Continued surveillance for rare long-term side effects should address the medical risk issue. Alternative primary vaccine administration schedules are currently under study, and could lead to regimens permitting achievement of protective immunity in 6 months or less. Vaccine is not approved for use in children under the age of 15 years.

AB - The development of an effective vaccine for Lyme disease represents a major advance in the control of the most prevalent vector-borne disease in the United States. It has a definite place in the total approach to control of this disease. Its use should be restricted to individuals who are at moderate to high risk of exposure to infected vector ticks. Vaccinated individuals should not be complacent about other personal protection measures, because the vaccine is not uniformly effective and protective antibody levels decay rapidly. Booster doses will be necessary, but the intervals have not yet been determined. There is a theoretical concern about the possible induction of inflammatory arthritis through an autoimmune mechanism, but there is no evidence that this condition has clinical relevance. The impact of the current lawsuits on vaccine recommendations and use remains to be determined. Continued surveillance for rare long-term side effects should address the medical risk issue. Alternative primary vaccine administration schedules are currently under study, and could lead to regimens permitting achievement of protective immunity in 6 months or less. Vaccine is not approved for use in children under the age of 15 years.

UR - http://www.scopus.com/inward/record.url?scp=0035060468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035060468&partnerID=8YFLogxK

U2 - 10.1016/S0891-5520(05)70274-9

DO - 10.1016/S0891-5520(05)70274-9

M3 - Article

VL - 15

SP - 171

EP - 187

JO - Infectious Disease Clinics of North America

JF - Infectious Disease Clinics of North America

SN - 0891-5520

IS - 1

ER -